tradingkey.logo
tradingkey.logo
Search

Amphastar Pharmaceuticals Inc

AMPH
Add to Watchlist
16.870USD
-0.430-2.49%
Close 05/15, 16:00ETQuotes delayed by 15 min
753.02MMarket Cap
9.87P/E TTM

Amphastar Pharmaceuticals Inc

16.870
-0.430-2.49%
View Detailed Chart
Intraday
1m
30m
1h
D
W
M
D

Today

-2.49%

5 Days

-11.21%

1 Month

-22.65%

6 Months

-35.26%

Year to Date

-37.01%

1 Year

-32.14%

Key Insights

Amphastar Pharmaceuticals Inc's fundamentals are relatively healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 47 out of 155 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Hold, with the highest price target at 25.86.In the medium term, the stock price is expected to trend down.Despite a very weak market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Amphastar Pharmaceuticals Inc's Score

Industry at a Glance

Industry Ranking
47 / 155
Overall Ranking
128 / 4482
Industry
Pharmaceuticals

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score
Previous score

Media Coverage

Last 24 hours
Coverage Level

Very Low
Very High
Negative

Amphastar Pharmaceuticals Inc Highlights

StrengthsRisks
Amphastar Pharmaceuticals, Inc. is a biopharmaceutical company that focuses primarily on developing, manufacturing, marketing, and selling generic and proprietary injectable, inhalation, and intranasal products. Additionally, it sells insulin API products. Most of its finished products are used in hospital or urgent care clinical settings and are primarily contracted and distributed through group purchasing organizations and drug wholesalers. The Company manufactures and sells over 25 products, such as BAQSIMI (glucagon) nasal powder 3mg, Primatene MIST, Glucagon for Injection Emergency Kit, Enoxaparin, Naloxone and Other Marketed Products, including Cortrosyn (cosyntropin for injection), Amphadase, Epinephrine injection, Lidocaine jelly, Lidocaine topical solution, Phytonadione injection, and others. The Company manufactures and sells two API products, Recombinant Human Insulin (RHI API) and porcine insulin API, for the injectable insulin market.
Undervalued
The company’s latest PE is 9.87, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 35.15M shares, decreasing 11.16% quarter-over-quarter.
Held by CI Select Canadian Equity Fund
Star Investor CI Select Canadian Equity Fund holds 588.00 shares of this stock.

Analyst Rating

Based on 7 analysts
Hold
Current Rating
25.857
Target Price
+41.14%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Amphastar Pharmaceuticals Inc News

More news coming soon, stay tuned...

Financial Indicators

EPS

Relevant data have not been disclosed by the company yet.

Total revenue

Relevant data have not been disclosed by the company yet.

Amphastar Pharmaceuticals Inc Info

Amphastar Pharmaceuticals, Inc. is a biopharmaceutical company that focuses primarily on developing, manufacturing, marketing, and selling generic and proprietary injectable, inhalation, and intranasal products. Additionally, it sells insulin API products. Most of its finished products are used in hospital or urgent care clinical settings and are primarily contracted and distributed through group purchasing organizations and drug wholesalers. The Company manufactures and sells over 25 products, such as BAQSIMI (glucagon) nasal powder 3mg, Primatene MIST, Glucagon for Injection Emergency Kit, Enoxaparin, Naloxone and Other Marketed Products, including Cortrosyn (cosyntropin for injection), Amphadase, Epinephrine injection, Lidocaine jelly, Lidocaine topical solution, Phytonadione injection, and others. The Company manufactures and sells two API products, Recombinant Human Insulin (RHI API) and porcine insulin API, for the injectable insulin market.
Ticker SymbolAMPH
CompanyAmphastar Pharmaceuticals Inc
CEOZhang (Yongfeng Yongfeng)
Websitehttps://amphastar.com/
KeyAI